GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kezar Life Sciences
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases. Its stock price is driven by news of clinical trials. The chart reflects the potential of its innovative treatment approach.
Share prices of companies in the market segment - Pharma immune
Kezar Life Sciences is a biopharmaceutical company developing drugs for the treatment of autoimmune diseases and oncology by targeting the proteasome and protein pathways. We've classified it in the Pharma: Immunology category. The chart below shows how investors are evaluating new approaches in this field.
Broad Market Index - GURU.Markets
Kezar Life Sciences is a biopharmaceutical company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. Its innovative approach makes it a component of the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
KZR - Daily change in the company's share price Kezar Life Sciences
Kezar Life Sciences, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its autoimmune disease drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Kezar Life Sciences, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with KZR, which focuses on autoimmune disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Kezar Life Sciences is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kezar Life Sciences
Kezar Life Sciences' year-to-date performance is a story of its drug development for the treatment of autoimmune diseases. Its 12-month market cap is entirely dependent on clinical trial data for its seco-proteasome inhibitor. Positive results could offer a new approach to treating conditions such as lupus nephritis.
Annual dynamics of market capitalization of the market segment - Pharma immune
Kezar, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its immunology drugs. Its stock price will reflect investors' speculative beliefs.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kezar Life Sciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biotech company focused on autoimmune diseases and oncology. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its proteasome inhibitor is generating strong investor reaction.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing drugs for the treatment of autoimmune diseases and oncology. Its scientific approach is based on proteasome inhibition. The dynamics of the biotech sector demonstrates the general appetite of investors for risky but potentially breakthrough technologies. The chart below provides the backdrop against which Kezar demonstrates the viability of its platform.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company developing new treatments for autoimmune diseases and cancer. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to demonstrate how its scientific data and trial progress have driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kezar Life Sciences
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases and cancer. Its weekly stock price is volatile and depends on clinical trial results that could confirm or refute the potential of its innovative approaches.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases and cancer. Its weekly stock price is volatile and depends on clinical trial results that could confirm or refute the potential of its innovative approaches.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kezar, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A chart comparing it to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
KZR - Market capitalization of the company Kezar Life Sciences
Kezar Life Sciences' market capitalization is a story about developing new treatments for autoimmune diseases and cancer. The company's stock price reflects investor hopes for its proteasome inhibitors. Its volatility reflects how the market views the scientific data and potential of its drugs.
KZR - Share of the company's market capitalization Kezar Life Sciences within the market segment - Pharma immune
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune diseases and cancer. Its share of its segment's market capitalization reflects the potential of its scientific platform. The chart below shows the valuation volatility dependent on clinical trial progress.
Market capitalization of the market segment - Pharma immune
Kezar Life Sciences is a biopharmaceutical company developing drugs for the treatment of autoimmune diseases and oncology. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. It illustrates the potential of new approaches to modulating the immune system to combat a wide range of diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph shows a new approach to treating autoimmune diseases. Kezar Life Sciences is developing drugs that target the cellular "wastebasket"—the proteasome. Their pipeline is a bet that this innovative mechanism of action will prove effective.
Book value capitalization of the company, segment and market as a whole
KZR - Book value capitalization of the company Kezar Life Sciences
Kezar Life Sciences' foundation is its scientific platform for discovering drugs that inhibit the proteasome and protein secretion pathways for the treatment of autoimmune diseases. This represents cutting-edge scientific capital. The chart shows how the biotech company is managing its resources for clinical testing of its unique approach to immunology.
KZR - Share of the company's book capitalization Kezar Life Sciences within the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing new treatments for autoimmune diseases and cancer. Its assets are R&D laboratories. The chart shows the minimum share of physical assets.
Market segment balance sheet capitalization - Pharma immune
The BCap_Ges chart for biotech clearly demonstrates how much lighter this sector is than heavy industry. Kezar Life Sciences thrives in this environment, where the barriers to entry are intellectual rather than physical. Its main asset is not its factories, but its unique scientific platform in immunology. Its entire capital is invested in patents and clinical data, not in expensive production infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Kezar Life Sciences' assets include capital and laboratories for developing drugs targeting the proteasome and protein metabolism. The book value provides the financial and scientific basis for the creation of a new class of therapeutics for the treatment of autoimmune diseases and cancer.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kezar Life Sciences
Kezar Life Sciences is an immunology company. Its value lies in its scientific platform. Its book value is small. Its market capitalization is a measure of its unique approach to treating autoimmune diseases. MvsBCap's price chart will be driven entirely by news of clinical trials that will confirm or refute its hypothesis.
Market to book capitalization ratio in a market segment - Pharma immune
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases and cancer. Its value lies in its scientific platform. The chart shows how the market views its innovative approach to drug discovery.
Market to book capitalization ratio for the market as a whole
Kezar Life Sciences develops new treatments for autoimmune diseases and oncology. Its scientific platform focuses on novel targets. The company's market valuation reflects investors' belief in the breakthrough potential of its science. The chart shows the premium the market places on innovative approaches in medicine.
Debts of the company, segment and market as a whole
KZR - Company debts Kezar Life Sciences
Kezar, a biotech company developing a new class of drugs to treat autoimmune diseases and cancer, is dedicating all of its capital to clinical trials. This chart shows how the company funds its cutting-edge research, which could offer new approaches to treating complex diseases, while managing financial risk.
Market segment debts - Pharma immune
Kezar Life Sciences is a clinical-stage biotech company developing drugs to treat autoimmune diseases. Funding long-term, expensive research before commercialization is a key challenge for such companies. Debt instruments are part of a complex financial strategy. The chart below reflects Kezar's approach to capital management.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kezar Life Sciences
Kezar Life Sciences is a biotech company developing drugs for autoimmune diseases. This chart shows its reliance on external funding for its innovative research. High debt is typical for biotech companies, but it also means the company's future is entirely dependent on positive clinical trial results.
Market segment debt to market segment book capitalization - Pharma immune
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases and cancer. The chart shows the sector's leverage. It helps understand how the company finances its innovative research focused on new molecular targets and how its financial model balances the risks in this field.
Debt to book value of all companies in the market
Kezar Life Sciences is a biotech company developing new treatments for autoimmune diseases and cancer. This chart, which shows the overall availability of capital in the market, is critically important. Funding for breakthrough but risky medical research is directly dependent on investor sentiment and the overall health of financial markets.
P/E of the company, segment and market as a whole
P/E - Kezar Life Sciences
For Kezar Life Sciences, a company focused on autoimmune diseases, this chart reflects investor confidence in its innovative approach. High values indicate hopes that its proteasome-targeted drugs could offer a new treatment for diseases such as lupus and dermatomyositis.
P/E of the market segment - Pharma immune
This chart shows the average P/E for the biotech sector, where Kezar Life Sciences is focused on autoimmune diseases. The industry's high valuation reflects hopes for breakthroughs. This metric serves as a benchmark for assessing how innovative the market perceives Kezar's technology.
P/E of the market as a whole
Kezar Life Sciences is a biotech company developing new drugs for the treatment of autoimmune diseases and cancer. Its approach is based on the inhibition of proteasomes and signaling pathways. This chart shows biotech sentiment. It helps understand how the market values Kezar's scientific platform and how clinical trial data impacts its valuation relative to other immunology companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kezar Life Sciences
Kezar Life Sciences is a biotech company developing drugs for the treatment of autoimmune diseases and cancer that target novel biological targets. This chart reflects analysts' belief that its innovative scientific approach will lead to the creation of effective treatments for patients with serious diseases.
%20P%2FE%20Kezar%20Life%20Sciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kezar-Life-Sciences&v=1772513799959 "Chart of the company's future (projected) P/E Kezar Life Sciences")
Future (projected) P/E of the market segment - Pharma immune
Kezar Life Sciences develops small-molecule drugs for the treatment of autoimmune diseases and cancer, targeting novel protein targets. This chart shows analysts' estimates of its future revenue, reflecting their confidence in its scientific platform and potential for breakthrough drug development.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513800023 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Kezar Life Sciences is a biotech company developing new treatments for autoimmune diseases and cancer. This is cutting-edge science. This chart, reflecting investors' overall risk appetite, is vital for Kezar. Market optimism allows it to attract capital for complex and expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513800026 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kezar Life Sciences
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases and cancer. Its financial activities are focused on clinical trials. This chart illustrates investments in innovative treatment approaches that can generate significant returns if successful but require significant upfront costs.
Profit of companies in the market segment - Pharma immune
Kezar Life Sciences is a biotechnology company developing small-molecule drugs for the treatment of autoimmune diseases and cancer, targeting novel targets. This graph illustrates the overall dynamics in the immunology sector, where a deep understanding of biological processes enables the creation of innovative drugs for the treatment of a wide range of serious diseases.
Overall market profit
Kezar Life Sciences is a biotech company focused on immunology and oncology. Like the entire sector, access to funding is vital. This graph, reflecting investors' risk appetite, impacts the ability of companies like Kezar to raise funds for their research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kezar Life Sciences
Kezar Life Sciences is a biotechnology company developing a new generation of drugs for the treatment of autoimmune diseases and cancer. Its approach is based on inhibiting protein debris in cells. This graph reflects analysts' expectations for the success of this innovative scientific platform in clinical trials.
%20profit%20of%20the%20company%20Kezar%20Life%20Sciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kezar-Life-Sciences&v=1772513800085 "Graph of future (projected) profit of the company Kezar Life Sciences")
Future (predicted) profit of companies in the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. The company's approach is based on inhibiting proteasomes and cellular signaling pathways. This chart shows profitability forecasts for the biotech sector, providing insight into the overall investment climate in immunology and oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513800097 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Kezar Life Sciences is a biotech company developing new treatments for autoimmune diseases and cancer. Its research requires significant, long-term investment. This graph, reflecting overall market sentiment, impacts the availability of capital for companies working at the forefront of science but with an uncertain payback period.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513800117 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kezar Life Sciences
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases. This chart shows the valuation of its innovative scientific platform. The high valuation reflects the potential of its approaches to create a new class of drugs.
P/S market segment - Pharma immune
Kezar Life Sciences is a biopharmaceutical company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. This chart shows the average revenue estimate in the biotech sector. It helps us understand the premium investors are placing on the potential of Kezar's innovative approaches to modulating the immune system.
P/S of the market as a whole
Kezar Life Sciences is a biotech company developing a new class of drugs targeting the proteasome to treat autoimmune diseases and cancer. Their scientific approach opens new therapeutic possibilities. This chart, showing the valuation of companies with real revenue, highlights the high expectations investors have for innovative scientific platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kezar Life Sciences
Kezar Life Sciences is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. This chart reflects investor expectations for its innovative approaches. The valuation is based on the potential of its candidates, which target novel biological targets to create breakthrough therapies.
%20P%2FS%20Kezar%20Life%20Sciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kezar-Life-Sciences&v=1772513800155 "The graph of the company's future (projected) P/S Kezar Life Sciences")
Future (projected) P/S of the market segment - Pharma immune
Kezar Life Sciences is a biopharmaceutical company developing new immunoproteasome-targeted therapies for autoimmune diseases and cancer. This is an innovative approach to immunology. This chart shows how the market values its scientific platform compared to the biotech sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513800160 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases and cancer. This chart, reflecting the biotech investment climate, directly impacts Kezar. Investors' willingness to invest in long-term, risky projects, which increases during periods of optimism, is vital for funding the company's research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513800187 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kezar Life Sciences
Kezar Life Sciences is a biopharmaceutical company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. This chart reflects revenue from strategic partnerships with major pharmaceutical companies. It shows financial support for innovative treatment approaches targeting key protein complexes in cells.
Sales of companies in the market segment - Pharma immune
Kezar Life Sciences, Inc. is a biotechnology company developing small-molecule therapeutics for the treatment of autoimmune diseases and cancer. Its business is segmented into two main platforms, targeting the immunoproteasome and the protein secretion pathway. This chart depicts the financial flows associated with one of its lead candidates.
Overall market sales
Kezar Life Sciences is a biotechnology company developing drugs to treat autoimmune diseases and cancer. Its innovative approach focuses on novel cellular targets. The company's value is determined by its scientific potential. It is an example of how fundamental science can lead to the creation of next-generation drugs that transform patients' lives.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biotechnology company developing novel drugs for the treatment of autoimmune diseases and cancer by inhibiting the secrin pathway and proteasome. Future sales projections are based on the success of its innovative approaches in these challenging therapeutic areas.
%20sales%20of%20the%20company%20Kezar%20Life%20Sciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kezar-Life-Sciences&v=1772513800231 "Schedule of future (projected) sales of the company Kezar Life Sciences")
Future (projected) sales of companies in the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing new drugs to treat autoimmune diseases and cancer. This chart shows expectations for the entire immunotherapy sector. It helps assess the progress analysts are predicting in developing targeted therapies that target specific proteins.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513800236 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Kezar Life Sciences, a biotech company focused on immunology and oncology, is dependent on raising capital for its growth. This graph of overall sales forecasts reflects the overall market sentiment, which determines the availability of funding for companies in clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513800239 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biotechnology company developing novel treatments for autoimmune diseases and cancer by inhibiting the secosome. This chart reflects its financial trajectory, where significant investments in cutting-edge science are the foundation for the development of future, potentially breakthrough drugs.
Market segment marginality - Pharma immune
Kezar Life Sciences is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. The effectiveness of their R&D platform is key to the development of new treatments. The chart shows their operating model and financial discipline compared to other players in the immunology field.
Market marginality as a whole
Kezar Life Sciences is a biotech company developing new treatments for autoimmune diseases and cancer. Its approach is based on proteasome inhibition. This graph shows the profitability of mature businesses, while KZR's value is determined by the potential of its unique scientific platform to create a new class of drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Kezar Life Sciences
Kezar Life Sciences is a biotech company developing new drugs to treat autoimmune diseases. This graph shows its team of scientists and clinicians. This team's growth is directly related to advancing its innovative molecules through costly clinical trials.
Share of the company's employees Kezar Life Sciences within the market segment - Pharma immune
Kezar Life Sciences is a biotechnology company developing new treatments for autoimmune diseases and cancer. Its innovative approaches require a strong scientific team. This indicator reflects the company's commitment to creating treatments for patients with severe and debilitating diseases.
Number of employees in the market segment - Pharma immune
Kezar Life Sciences is developing new immunoproteasome-targeted drugs for the treatment of autoimmune diseases and cancer. This chart shows employment in the immunology sector. The growing number of scientists in this field reflects the deep understanding of the immune system and the search for new targets for the development of more effective and safer drugs.
Number of employees in the market as a whole
Kezar Life Sciences is a biopharmaceutical company developing drugs to treat autoimmune diseases. Its headcount and market cap depend on scientific breakthroughs. This chart reflects overall headcount, but for Kezar, the publication of breakthrough data will be far more significant.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kezar Life Sciences (KZR)
Kezar Life Sciences, Inc. is a biotech company developing drugs to treat autoimmune diseases and cancer. The very high market capitalization per employee in this chart is typical for a clinical-stage biotech. The entire value represents the company's hope for the future success of its scientific platform.
%20of%20the%20company%20Kezar%20Life%20Sciences%20(KZR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kezar-Life-Sciences-KZR&v=1772513800336 "Chart of market capitalization per employee (in thousands of dollars) of the company Kezar Life Sciences (KZR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Kezar Life Sciences is a biopharmaceutical company developing new treatments for autoimmune diseases and cancer. In immunology, this metric reflects investors' assessment of their scientific platform and the potential of their clinical candidates. It is a measure of the perceived value of their innovative approaches.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513800338 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Kezar Life Sciences is a biotech company developing drugs for the treatment of autoimmune diseases and cancer that target novel targets. The chart reflects the market's high appreciation for their innovative scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513800354 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kezar Life Sciences (KZR)
Kezar Life Sciences (KZR) is a biopharmaceutical company developing new treatments for autoimmune diseases and cancer. They focus on inhibiting the secretome and proteasome. They are an R&D company. This graph (negative) shows how much capital is burned per scientist working on this complex but potentially breakthrough scientific platform.
%20Chart%20Kezar%20Life%20Sciences%20(KZR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kezar-Life-Sciences-KZR&v=1772513800356 "Company Profit Per Employee (in thousands of dollars) Chart Kezar Life Sciences (KZR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases and cancer. In this field, R&D efficiency is key. This chart shows the value their scientific team creates and allows them to evaluate the productivity of their research platform against their competitors.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513800357 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Kezar Life Sciences (KZR) is a biotech R&D company focused on immunology and oncology. Like others, it has no commercial products. This negative metric reflects the cost of maintaining a top-notch research team. It shows investors the investment in personnel working on developing future breakthrough drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513800358 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kezar Life Sciences (KZR)
Kezar Life Sciences is a biopharmaceutical company developing drugs for the treatment of autoimmune diseases and cancer. Currently in the clinical stage, its revenue depends on partner fees. This graph will indicate the future commercial success of its innovative approaches.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kezar-Life-Sciences-KZR&v=1772513800359 "Sales chart per company employee Kezar Life Sciences (KZR)")
Sales per employee in the market segment - Pharma immune
Kezar Life Sciences is a biotech company developing drugs to treat autoimmune diseases (lupus) and cancer. This chart compares their revenue per employee (R&D) to the industry average. This shows how productive their R&D is compared to that of other biotech companies.
Sales per employee for the market as a whole
Kezar Life Sciences (KZR) is a clinical-stage biotech company developing drugs for the treatment of autoimmune diseases (lupus) and cancer. The company has no commercial sales revenue. This chart will reflect $0 or partnership revenue, as the company's focus is on R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Kezar Life Sciences (KZR)
Kezar Life Sciences (KZR) is a biotech company developing drugs to treat autoimmune diseases (lupus). It's a complex and competitive market. This chart shows the number of investors skeptical of Kezar's scientific platform and its chances of competing with blockbuster drugs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kezar-Life-Sciences-KZR&v=1772513800377 "Short Shares Chart for the Company Kezar Life Sciences (KZR)")
Shares shorted by market segment - Pharma immune
Kezar Life Sciences (KZR) is a biotech company developing drugs to treat autoimmune diseases (lupus) and cancer. They target the cellular "garbage bin"—the proteasome. This chart shows bets against the immunology sector, reflecting the high investor skepticism regarding the success of clinical trials in this competitive field.
Shares shorted by the overall market
Kezar Life Sciences is a biotech company targeting autoimmune diseases. Their developments require hundreds of millions of dollars and years of research. This chart reflects the general pessimism. When fear prevails, investors look at the balance sheet. They see that KZR is burning through cash and fear that in a crisis, the company will not be able to attract the new capital needed to survive.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kezar Life Sciences (KZR)
Kezar Life Sciences (KZR) develops treatments for autoimmune diseases and cancer. Like many biotechs, the stock experiences sharp ups and downs on trial news. This oscillator helps measure the strength of these movements. Zones above 70 and below 30 indicate when the price reaches extremes, which may signal an imminent reversal or a pause in the trend.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kezar-Life-Sciences-KZR&v=1772513800397 "RSI 14 indicator chart for the company's stock Kezar Life Sciences (KZR)")
RSI 14 Market Segment - Pharma immune
Kezar (KZR) is a biotech company developing a new class of drugs (proteasome inhibitors) for the treatment of severe autoimmune diseases such as lupus. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether the entire sector is overheated by hype surrounding new treatments or oversold by the downturn.
RSI 14 for the overall market
Kezar Life Sciences (KZR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KZR (Kezar Life Sciences)
Kezar (KZR) is a biopharmaceutical company developing small molecule drugs for the treatment of autoimmune diseases (lupus nephritis) and oncology. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KZR-Kezar-Life-Sciences&v=1772513800424 "A chart showing analyst consensus forecasts for the expected stock price. KZR (Kezar Life Sciences)")
The difference between the consensus estimate and the actual stock price KZR (Kezar Life Sciences)
Kezar Life Sciences is a biotech company developing a new class of drugs (inhibitors) for the treatment of autoimmune diseases (lupus) and cancer. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this innovative scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KZR-Kezar-Life-Sciences&v=1772513800428 "A chart showing the difference between the consensus forecast and the actual stock price. KZR (Kezar Life Sciences)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Kezar (KZR) is a biotech company developing a new class of drugs (immunoproteasome inhibitors) for the treatment of severe autoimmune diseases (lupus, myositis). This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe this complex R&D approach will be successful.
Analysts' consensus forecast for the overall market share price
Kezar Life Sciences (KZR) is a clinical-stage biopharmaceutical company focused on treating autoimmune diseases (lupus) and cancer. This chart shows the overall market risk appetite. It serves as an indicator of the "open" or "closed" funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biotech company focused on immunology. Their signature R&D platform targets the proteasome (the cellular protein recycling system) to create new drugs for the treatment of lupus and other autoimmune diseases. This graph is a clear indicator of their R&D progress, reflecting their clinical trial progress.
AKIMA Market Segment Index - Pharma immune
Kezar Life Sciences (KZR) is a biotech company developing small-molecule drugs for the treatment of autoimmune diseases (lupus, nephritis) and cancer through proteasome inhibition. The chart shows the average index for the segment, helping investors assess how this targeted strategy compares to the average in the immune pharma sector.
The AKIM Index for the overall market
Kezar Life Sciences is a biotech company developing proteasome inhibitors for the treatment of autoimmune diseases (lupus nephritis). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop, which is critical for funding this research platform.
